When was VitaDX founded?

VitaDX was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is VitaDX located?

VitaDX is headquartered in Evry Courcouronnes, France.

How many employees does VitaDX have?

As of Aug 31, 2026, the latest employee count at VitaDX is 24.

Is VitaDX a funded company?

VitaDX is a funded company, having raised a total of $23.3M across 10 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 16, 2015.

When was the latest funding round of VitaDX?

VitaDX's latest funding was a $***** Series B round on Aug 22, 2025, with participation from 2 investors.

Where does VitaDX rank among its competitors?

VitaDX ranks 1st amongst 20 active competitors, of which 8 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Vesica Health, which secured $4.47M in Mar, 2026.

Who are the top competitors of VitaDX?

VitaDX's top competitors include Vesica Health, Nucleix and OncoDiag. Among them, Vesica Health secured the most recent funding round in March, 2026.

VitaDX - 2026 Company Profile, Team, Funding & Competitors

VitaDX is a series B company based in Evry Courcouronnes (France), founded in 2015 by Thibaut Troude. It operates as an Early diagnostics for bladder cancer. VitaDX has raised $23.3M in funding from Odyssee Venture. The company has 20 active competitors, including 8 funded and 3 that have exited. Its top competitors include companies like Vesica Health, Nucleix and OncoDiag.

Company Details

VitaDx develops early diagnostics for bladder cancer. The company uses a proprietary protocol that uses digital analysis to analyze urine and detect selective fluorescence around bladder cancer cells. VitaDx claims that this fluorescence detects cells with greater accuracy and sensitivity than traditional staining protocols, even in early stages of the disease.

Website: vitadx.com
Phone Number: +33 **********

Key Metrics

Founded Year

2015

Location

Evry Courcouronnes, France

Stage

Series B

Total Funding

$23.3M in 10 rounds

Latest Funding Round

Series B, Aug 22, 2025, $*****

Investors

Odyssee Venture & 10 more

Ranked

1^st among 20 active competitors

Employee Count

24 as on Aug 31, 2026

Similar Companies

Vesica Health & 23 more

View VitaDX's full profile

VitaDX has raised a total funding of $23.3M over 10 rounds. Its first funding round was on Jun 16, 2015. Its latest funding round was a Series B round on Aug 22, 2025 for $*****. 2 investors participated in its latest round. VitaDX has 10 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of VitaDX:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 22, 2025	3907249	Series B	4063645	6249577	8030872	7926503
Oct 08, 2024	8305591	Series B	8755129	7425518	6620231	4141782
Apr 2024	1061974	Series A	9196870	5372715	6552284	5512636

Access funding benchmarks and valuations. Sign up today!

View details of VitaDX's funding rounds and investors

The founders of VitaDX is Thibaut Troude.

Here are the details of VitaDX's key team members:

Thibaut Troude: Co-Founder & CTO of VitaDX.
Contact Info: 1 email address

View details of VitaDX's Founder profiles and Board Members

VitaDX's employee count trend

VitaDX has 24 employees as of Aug 26. Here is VitaDX's employee count trend over the years:

Uncover VitaDX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VitaDX include Vesica Health, Nucleix and OncoDiag. Here is the list of Top 10 competitors of VitaDX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	VitaDX 2015, Evry Courcouronnes (France), Series B	Early diagnostics for bladder cancer	$23.3M	BNP Paribas, Caisse D Epargne & 9 others	48/100
2nd	Vesica Health 2022, Irvine (United States), Acquired	Provider of noninvasive tests to improve the early detection and treatment of bladder cancer for physicians and hematuria patients	$4.47M	-	46/100
3rd	Nucleix 2008, Rehovot (Israel), Series C	Developer non-invasive molecular cancer diagnostic tests	$88.5M	RA Capital Management, Sands Capital & 10 others	46/100
4th	OncoDiag 2013, Miserey (France), Series A	Developer of non-invasive cancer diagnostic solutions	$4.2M	Paris Business Angels, Angels Sante & 3 others	36/100
5th	PhageTech 2014, Newport Beach (United States), Series A	Your source for SGP lottery results, data, and Singapore Togel	$2.9M	EvoNexus, Black River & 4 others	36/100
6th	Early Is Good 2019, Indianapolis (United States), Seed	Developer of multi-omic platform for biomarker detection to transform healthcare	$4M	Social Capital, HHS	36/100
7th	InnoTech Precision Medicine 2021, Boston (United States), Funding Raised	Developer of multimodal molecular diagnostic platform for early disease detection	-	HHS	34/100
8th	KDx Diagnostics 2016, Los Gatos (United States), Seed	Provider of urine and bladder test to detect cancer	$1.12M	-	33/100
9th	Sienna Diagnostics 2002, Scoresby (Australia), Public	Developer of in-vitro diagnsotics tests for the detection of cancer	$3.05M	-	33/100
10th	Cellens 2020, Medford (United States), Series A	Developer of non-invasive diagnostic technology for the detection of bladder cancer	$6.94M	IndieBio	32/100